Clinical Trial

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Study acronym: Enith2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
Protocol Amendment History 5 changes
notable Trial sites expanded: 122 -> 163 locations 2026-07-21
notable Trial sites expanded: 61 -> 122 locations 2026-06-24
notable Trial sites expanded: 36 -> 61 locations 2026-05-27
notable Trial sites expanded: 28 -> 36 locations 2026-04-25
notable Trial sites expanded: 3 -> 28 locations 2026-04-15
Trial Details
NCT Number NCT07351058
Lead Sponsor Hoffmann-La Roche
Conditions Obesity or Overweight, Type 2 Diabetes Mellitus
Enrollment 1,600 participants
Start Date 2026-03-23
Primary Completion 2028-08-07 (estimated)
Study Completion 2028-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-20